Open Access

Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates

  • Takahiro Seno1,
  • Aihiro Yamamoto1,
  • Yuji Kukida1,
  • Aiko Hirano1,
  • Takashi Kida1,
  • Amane Nakabayashi1,
  • Kazuki Fujioka1,
  • Hidetake Nagahara1,
  • Wataru Fujii1,
  • Ken Murakami1,
  • Ryo Oda2,
  • Hiroyoshi Fujiwara2,
  • Masataka Kohno1 and
  • Yutaka Kawahito1Email author

Received: 12 April 2016

Accepted: 28 June 2016

Published: 11 July 2016



Patients with glucocorticoid-induced osteoporosis (GIOP) are at very high risk of fracture, and patients with severe GIOP often experience fractures during treatment with bisphosphonates. Teriparatide (TPTD) is the only currently available anabolic agent expected to be effective for GIOP. Once-weekly TPTD decreased bone resorption marker with primary osteoporosis different from daily TPTD, but it has not yet been tested with GIOP.


To evaluate the efficacy of once-weekly TPTD for patients with GIOP and inadequate response to bisphosphonates.


Patients with GIOP and collagen diseases treated with prednisolone for at least 6 months with inadequate responses to bisphosphonates were administered once-weekly TPTD. Bone density of the lumbar spine and femoral neck, measured as percent young adult mean (YAM); serum concentrations of cross-linked N-terminal telopeptides of type I collagen (NTx), bone alkaline phosphatase (BAP), and calcium; and FRAX were measured at baseline and 6, 12 and 18 months after starting TPTD.


Of the 12 GIOP patients with collagen diseases enrolled, nine (seven females, two males; mean age 57.4 ± 11.1 years) completed treatment, including six with systemic lupus erythematosus, two with rheumatoid arthritis, and one with adult onset still disease. Only one new fracture event, a lumbar compression fracture, occurred during the study period, although seven patients experienced eight fracture events within 18 months before starting TPTD (p = 0.04). Lumbar spine YAM significantly improved at 18 months (p = 0.04), whereas femoral neck YAM did not (p = 0.477). Serum NTx, BAP, Ca, and FRAX were not significantly affected by TPTD treatment.


Once-weekly TPTD reduces fracture events and increases bone density of the lumbar spine of GIOP patients with inadequate response to bisphosphonates.


Teriparatide Once-weekly Glucocorticoid Osteoporosis Bisphosphonate


Glucocorticoids are widely utilized to treat many collagen diseases. Due to their extensive use, glucocorticoid therapy is the most common cause of secondary and drug-induced osteoporosis. The pathophysiology of glucocorticoid-induced osteoporosis (GIOP) is multi-factorial, with osteoblastic dysfunction being an important aspect in the mechanism of glucocorticoid effects (Dalle Carbonare et al. 2005; (Patschan et al. 2001). Moderate doses of oral glucocorticoids inhibit synthesis of bone collagen by osteoblasts and the conversion of precursor cells into functioning osteoblasts (Patschan et al. 2001). Moreover, oral glucocorticoids were shown to have direct pro-apoptotic effects on osteoblasts in a mouse model (O’Brien et al. 2004). Glucocorticoids also modify the synthesis, release, and receptor binding of locally produced growth factors (Canalis 1996). These adverse effects of glucocorticoids on bone formation reduce the total amount of bone (Dalle Carbonare et al. 2005). Agents that promote bone formation are needed for patients with GIOP.

Teriparatide (TPTD), a human parathyroid hormone analog, is the only currently available anabolic agent that stimulates osteoblast activity (Borggrefe et al. 2010); (Sibai et al. 2011). TPTD has been shown to increase bone mass, improve bone quality, and reduce the risk of fracture in patients with severe osteoporosis (Toulis et al. 2011). Daily administration of recombinant TPTD has been shown to be effective in the treatment of nonunion fractures (Oteo-Alvaro and Moreno 2010); (Lee et al. 2012). Daily TPTD increased bone mineral density more than alendronate in GIOP (Saag et al. 2007). Although assays of markers of bone metabolism showed that daily TPTD increased markers of bone formation and bone resorption, the balance favored bone formation (Miyauchi et al. 2010).

Once-weekly chemically synthesized TPTD has been shown to have rapid and powerful anti-fracture activity (Nakamura et al. 2012); (Nakano et al. 2014), increasing the bone mineral density (BMD) of cancellous but not cortical bone (Sone et al. 1995). Once-weekly TPTD significantly reduced NTx levels from baseline by 12.2 % at 48 weeks and thereafter (Nakamura et al. 2012). This reduction of bone resorption activity is the unique feature of once-weekly TPTD although daily TPTD increase bone resorption marker (McClung et al. 2005). Even after treatment with bisphosphonates, once-weekly TPTD injections reduced the risk of vertebral fracture and increased BMD with primary osteoporosis subjects. Glucocorticoid promotes bone resorption activity in addition to the reduction of bone formation. Therefore, these findings suggested that once-weekly TPTD may be effective in patients with GIOP. This pilot study assessed the efficacy of once-weekly TPTD for GIOP patients with inadequate response to bisphosphonates.


Study design

The study cohort consisted of patients at our institution with GIOP and collagen diseases, who showed inadequate responses to bisphosphonates. Patients received subcutaneous injections of 56.5 μg of TPTD once-weekly for 18 months. During the study, all the patient concomitantly received vitamin D. Markers of osteoporosis were assessed at baseline and after 6, 12 and 18 months of treatment. The study protocol was approved by the responsible institutional review boards at our hospital (RBMR-C-1154-3), was conducted in accordance with the ethical standards of the Declaration of Helsinki, and was consistent with good clinical practice.


Osteoporosis was diagnosed according to the guidelines on the management and treatment of GIOP of the Japanese Society for Bone and Mineral Research (Nawata et al. 2005), i.e., with BMD at the lumbar spine or femoral neck <80 % of the young adult mean (YAM) in the Japanese population. Moreover, all patients were treated with corticosteroids for at least 6 months, but experienced new fractures or decreased BMD despite treatment with bisphosphonates, after which patients were started on once-weekly TPTD instead of bisphosphonates. All patients provided written informed consent.

Efficacy measures

Bone mineral density of the lumbar spine and hip was measured in nine and six subjects, respectively, using dual-energy x-ray absorptiometry (Discovery Wi; Hologic, Bedford, MA) at baseline and at 6, 12 and 18 months. BMD and YAM were determined, and changes from baseline were calculated.

Serum samples were obtained under nonfasting conditions before injection of TPTD. All measurements were performed centrally in a single batch at our hospital and a validated institution (SRL, Tokyo, Japan). Serum concentrations of the bone formation marker bone alkaline phosphatase (BAP); the bone resorption marker cross-linked N-telopeptide of type I collagen (NTx), and calcium were measured at baseline and after 6, 12 and 18 months. Serum BAP was measured using a chemiluminescent enzyme immunoassay and serum NTx by enzyme-linked immunoassay.


Morphometric fractures were assessed in frontal and lateral spine, and hip radiographs were obtained at baseline and after 6, 12 and 18 months. Clinical fractures were defined as those confirmed on radiographs, accompanied by clinically evident symptoms such as pain in the vertebral or non-vertebral region. Both morphometric and clinical fractures were counted as fracture events.

The fracture risk assessment tool (FRAX) is a scientifically validated risk assessment tool endorsed by the World Health Organization that assesses the 10-year probability of fracture. Ten-year probabilities of hip and major osteoporotic fractures were calculated using the official calculation web tool of the World Health Organization.

Adverse events

Patients underwent regular physical examinations, hematological monitoring, measurements of blood chemistry, and urinary examinations. All adverse events that led to withdrawal from the study were recorded.

Statistical analysis

Percent changes from baseline in BMD, YAM, FRAX, serum calcium, and bone turnover markers at each time point were compared with baseline measurements using ANOVA and Wilcoxon matched-pairs single rank tests. All statistical analysis were performed using GraphPad Prism statistical software (Version 5, GraphPad Software, San Diego, CA, USA), and all had a two-sided significance level of 0.05.



Twelve GIOP patients with collagen disease were enrolled into this study, including six with systemic lupus erythematosus (SLE), three with rheumatoid arthritis (RA), one with mixed connective tissue disease, one with systemic sclerosis, and one with adult onset still disease (AOSD). One patient stopped TPTD after the first dose due to nausea, and two discontinued within 6 months because of onset of another disease unassociated with TPTD, including one patient with malignant lymphoma and the other with purulent arthritis of the hip and abscess in the iliopsoas muscle. The remaining nine patients completed this study; their baseline demographic and clinical characteristics, including concentrations of bone metabolic markers, are shown in Table 1. The nine patients, of mean age 57.4 years, included six with SLE (five females and one male), two with RA (one female and one male), and one female with AOSD. At baseline, their mean BMD was 0.74 at the lumbar spine and 0.62 at the femoral neck, and their mean YAM at these two sites was 73.1 and 72.0 %, respectively. Prior to starting TPTD treatment, seven of the nine subjects experienced vertebral or non-vertebral fractures, including seven who experienced fractures within 18 months before this study, regardless of their BMD. In remaining two patients, BMD decreased in spite of bisphosphonate treatment. Mean BAP at baseline was 10.8 µg/L and mean serum NTx was 13.8 nmol BCE/L. All patients received the administration of vitamin D. Disease activities including DAS28-CRP and SLEDAI were not changed during study period.
Table 1

Baseline characteristics of patients who received once-weekly teriparatide injections for 18 months

Sex (n)

Female: 7, male: 2

Age (year)

57.4 ± 11.1

Disease (n)

SLE 6, RA 2, AOSD 1

PSL dose at baseline (mg/day)

10 ± 6.6

Fracture events within 18 months before TPTD treatment (n)

8 events of 7 patients

Lumbar spine YAM (%)

73.1 ± 11.9

Total hip YAM (%)

72 ± 10.0

Lumbar spine BMD

0.74 ± 0.11

Total hip BMD

0.62 ± 0.11

Ca (mg/dl)

9.1 ± 0.5

BAP (µg/L)

Reference value; male 3.7–20.9, Premenopausal female 2.9–14.5, Postmenopausal female 3.8–22.6

10.8 ± 4.6

Serum NTx (nmol BCE/L)

Reference value; Male 9.5–17.7, Premenopausal female 7.5–16.5, Postmenopausal female 10.7–24.0

13.8 ± 4.4

FRAX: major fracture (%)

20.5 ± 16.7

FRAX: hip fracture (%)

8.8 ± 11.4

Data are shown as mean ± SD

SLE systemic lupus erythematosus, RA rheumatoid arthritis, AOSD adult onset still disease, PSL prednisolone, YAM young adult mean, BMD bone mineral density, Ca calcium, BAP bone alkaline phosphatase, NTx type 1 collagen cross-linked N-telopeptide

Bone mineral density

At 18 months, YAM increased 8.27 % at the lumbar spine (p = 0.041, ANOVA; p = 0.019, Wilcoxon matched-pairs single rank test), but decreased −2.85 % at the femoral neck (p = 0.477, ANOVA) (Fig. 1a, b). BMD at these sites, however, did not change significantly during TPTD treatment (Fig. 1c, d), but tended to increase at the lumbar spine.
Fig. 1

Mean percent changes in bone density from baseline during TPTD treatment. Changes over time in a Lumbar spine YAM; b Femoral neck YAM; c Lumbar spine BMD; d Femoral neck BMD. Results were compared using ANOVA and Wilcoxon matched-pairs single rank test; *p < 0.05; bars indicate 95 % CI

Bone turnover markers

Serum BAP (Fig. 2a) and NTx (Fig. 2b) tended to increase during TPTD treatment, but not significantly. Serum calcium concentration was unchanged (Fig. 3).
Fig. 2

Mean percent changes in bone turnover markers from baseline during TPTD treatment. Percent changes over time in a mean BAP; and b mean serum NTx. Differences were compared using ANOVA; bars indicate 95 % CI. BAP was representative of bone formation marker, and NTx was for bone resorption marker

Fig. 3

Mean serum calcium concentration during TPTD treatment. Mean serum calcium concentrations over time. Differences were compared using ANOVA; bars indicate 95 % CI


FRAX for hip and major fractures remained constant during TPTD administration (Fig. 4a, b). The number of fracture events and patients with new fractures 18 months before or after TPTD treatment in Table 2. During the 18 months before TPTD treatment, seven patients experienced eight fracture events. During the 18 months of TPTD treatment, only one patient, a female with SLE, experienced a new radiographic vertebral fracture or investigator-assessed non-vertebral fracture (p = 0.04). This patient had three fracture events within 18 months before the start of the study, and showed a significant reduction from baseline in BAP concentration.
Fig. 4

Mean FRAX score during TPTD treatment. Changes over time in FRAX scores. a Major fractures; and b Hip fractures. Differences were compared using ANOVA; bars indicate 95 % CI

Table 2

Fracture events of patients who completed the 18-months study duration

Study period of TPTD administration

−18 ~ −13 months

−12 ~ −7 months

−6 ~ 0 months

0 ~ 6 months

7 ~ 12 months

13 ~ 18 months








Fracture events







This table shows the number of total fracture events and patients with new fractures before or after TPTD administration


Of the 12 patients enrolled, nine patients completed this study. One patient discontinued TPTD due to nausea at first administration. Through 18 months, none of the patients who completed this study experienced any significant adverse events.


This study indicated that once-weekly TPTD was effective for subjects with GIOP who were non-responsive to bisphosphonate therapy. TPTD reduced fracture events and increased BMD at the lumbar spine. Moreover, it was indicated the new sights of bone metabolism marker change in GIOP treated with once-weekly TPTD. The mean serum concentration of NTx, a bone resorption marker, increased during treatment, although former study showed NTx levels decreased under onece-weekly TPTD treatment of primary osteoporosis (Nakamura et al. 2012).

Glucocorticoid induces osteoporosis mainly by suppressing osteoblast-mediated osteogenesis. Glucocorticoids can suppress osteoblastic differentiation and activity, both of which many be overcome by PTH and bisphosphonates (Hayashi et al. 2009). An in vitro study showed that low-dose PTH reversed glucocorticoid-inhibited alkaline phosphatase activity (Iu et al. 2005). Intermittent PTH was found to prevent glucocorticoid-induced osteoblast and osteocyte apoptosis and preserve the rate of bone formation, BMD, and strength (Weinstein et al. 2010). These findings indicate that TPTD is suitable for treatment of GIOP.

TPTD is a unique anabolic agent that accelerates bone formation. Daily TPTD has been shown to reduce bone fractures, especially in the vertebrae, increasing BMD at the lumbar spine (Reeve et al. 1976), and reducing nonunion fractures (Aspenberg and Johansson 2010). Spine and hip BMD were increased more by daily TPTD than by alendronate in patients with GIOP (Saag et al. 2009). Additionally, daily TPTD for 18 months was superior to risedronate in improving lumbar spine BMD, as measured by quantitative computed tomography, in males with GIOP (Glüer et al. 2013).

Recently, once-weekly TPTD has been available for severe osteoporosis in addition to daily TPTD. One of the most important difference between once-weekly and daily TPTD is change in bone resorption marker. Once-weekly TPTD reduces bone resorption markers in addition to increasing bone formation markers, as compared to daily TPTD that increase bone resorption markers (Miyauchi et al. 2010). Glucocorticoid also promote bone resorption. Therefore, once-weekly TPTD is thought to be more suitable for GIOP treatment than daily TPTD.

The efficacy of once-weekly TPTD had not been tested for GIOP. A double-blinded randomized clinical trial for primary osteoporosis patients confirmed that once-weekly TPTD increased lumbar BMD dose-dependently after 24 and 48 weeks, although the radiogrammetric density of cortical bone did not differ significantly (Fujita et al. 1999). This study found that once-weekly TPTD for 18 months significantly increased YAM of the lumbar spine, as well as reducing fracture events. Prior fracture is an important risk factor for future fractures (Klotzbuecher et al. 2000). In our study, TPTD prevented the fracture events in the six patients who had one fracture event during 18 months before TPTD. A female SLE patient, who had two fractures within 18 months before starting TPTD, suffered only one fracture during TPTD treatment. Furthermore she was treated with denosumab after once-weekly TPTD, she did not fracture under denosumab. Swithing from TPTD to denosumab improved bone mineral density effectively in postmenopousal osteoporosis (Leder et al. 2015). Preseding once-weekly TPTD might be beneficial for prevention of fracture. Additionally, YAM was improved at 18 months in our study, but it was not increased at 12 months. We assumed the reason that patients enrolled in this study were very severe with osteoporosis. This fact showed that we needed TPTD treatment for 18 months in order to improve GIOP. Taken together, 18 months of once-weekly TPTD reduced fractures in GIOP patients.

Our study also indicated the new findings of bone turnover makers. Assessments of bone turnover makers during once-weekly TPTD administration found that the bone formation markers BAP and osteocalcin were increased, while the bone resorption marker urinary deoxypiridinoline was decreased (Sugimoto et al. 2014), as was urinary NTx (Nakamura et al. 2012). Thus, weekly TPTD not only enhances bone formation but suppresses bone resorption. Our study found, however, that the increase in BAP was smaller than previously reported and that serum NTx increased. Although daily TPTD tended to increase serum calcium level, weekly TPTD maintained calcium concentration (Sone et al. 1995). Our study found that serum calcium did not change during 18 months of treatment with once-weekly TPTD. This study, however, included only patients with severe GIOP who were unresponsive to bisphosphonates, which may have reduced the impact of TPTD on bone turnover markers.

Moreover, lower frequency of administration decreases the burden on patients and enhance the convenience. Thus, once-weekly administration has the advantage even if its beneficial effect is equivalent to daily TPTD.

This study had several limitations, including the very small size of the study population and the evaluation of only two bone turnover markers, BAP and NTx. Other markers of bone turnover, including osteocalcin, P1NP, and deoxypiridinoline, were not measured. Third, patients did not receive supplementary calcium and magnesium as basic treatment for osteoporosis.

In conclusion, this study is the first to our knowledge to show that once-weekly TPTD reduced fracture events and increased the YAM of the lumbar spine in GIOP patients with inadequate response to bisphosphonates. Once-weekly TPTD was well tolerated and compliance was good. Although these findings suggest that TPTD may be safe and effective for GIOP patients with collagen diseases, further studies in larger patient populations are required to determine the efficacy of once-weekly TPTD for GIOP.


Authors’ contributions

TS managed this study, enrolled patients in this study, and performed the statistical analysis. AY enrolled patients and helped to draft the manuscript. YK, AH, TK, AN, KF, HN, WF and KM enrolled patients. RO and HF helped for interpretation of X-ray. MK participated in study design. YK conceived of the study, and participated in its design and coordination. All authors read and approved the final manuscript.


We thank Chiaki Tani for secretarial assistance.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine


  1. Aspenberg P, Johansson T (2010) Teriparatide improves early callus formation in distal radial fractures. Acta Orthop 81:234–236. doi: View ArticleGoogle Scholar
  2. Borggrefe J, Graeff C, Nickelsen TN et al (2010) Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res 25:472–481. doi: View ArticleGoogle Scholar
  3. Canalis E (1996) Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 81:3441–3447. doi: Google Scholar
  4. Dalle Carbonare L, Bertoldo F, Valenti MT et al (2005) Histomorphometric analysis of glucocorticoid-induced osteoporosis. Micron 36:645–652. doi: View ArticleGoogle Scholar
  5. Fujita T, Inoue T, Morii H et al (1999) Effect of an intermittent weekly dose of human parathyroid hormone (1–34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporos Int 9:296–306. doi: View ArticleGoogle Scholar
  6. Glüer C-C, Marin F, Ringe JD et al (2013) Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 28:1355–1368. doi: View ArticleGoogle Scholar
  7. Hayashi K, Yamaguchi T, Yano S et al (2009) BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 379:261–266. doi: View ArticleGoogle Scholar
  8. Iu MF, Kaji H, Naito J et al (2005) Low-dose parathyroid hormone and estrogen reverse alkaline phosphatase activity suppressed by dexamethasone in mouse osteoblastic cells. J Bone Miner Metab 23:450–455. doi: View ArticleGoogle Scholar
  9. Klotzbuecher CM, Ross PD, Landsman PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739. doi: View ArticleGoogle Scholar
  10. Leder B, Tsai J, Uihlein A, Wallace P (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147–1155. doi: View ArticleGoogle Scholar
  11. Lee YK, Ha YC, Koo KH (2012) Teriparatide, a nonsurgical solution for femoral nonunion? A report of three cases. Osteoporos Int 23:2897–2900. doi: View ArticleGoogle Scholar
  12. McClung MR, San Martin J, Miller PD et al (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762–1768. doi: View ArticleGoogle Scholar
  13. Miyauchi A, Matsumoto T, Sugimoto T et al (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493–502. doi: View ArticleGoogle Scholar
  14. Nakamura T, Sugimoto T, Nakano T et al (2012) Randomized teriparatide [human parathyroid hormone (PTH) 1-34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097–3106. doi: View ArticleGoogle Scholar
  15. Nakano T, Shiraki M, Sugimoto T et al (2014) Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial. J Bone Miner Metab 32:441–446. doi: View ArticleGoogle Scholar
  16. Nawata H, Soen S, Takayanagi R et al (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23:105–109. doi: View ArticleGoogle Scholar
  17. O’Brien CA, Jia D, Plotkin LI et al (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835–1841. doi: View ArticleGoogle Scholar
  18. Oteo-Alvaro A, Moreno E (2010) Atrophyc humeral shaft nonunion treated with teriparatide (rh PTH 1-34): a case report. J Shoulder Elbow Surg 19:22–28. doi: View ArticleGoogle Scholar
  19. Patschan D, Loddenkemper K, Buttgereit F (2001) Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 29:498–505. doi: View ArticleGoogle Scholar
  20. Reeve J, Hesp R, Williams D et al (1976) Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1:1035–1038. doi: View ArticleGoogle Scholar
  21. Saag KG, Shane E, Boonen S et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039. doi: View ArticleGoogle Scholar
  22. Saag KG, Zanchetta JR, Devogelaer JP et al (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346–3355. doi: View ArticleGoogle Scholar
  23. Sibai T, Morgan EF, Einhorn TA (2011) Anabolic agents and bone quality. Clin Orthop Relat Res 469:2215–2224. doi: View ArticleGoogle Scholar
  24. Sone T, Fukunaga M, Ono S, Nishiyama T (1995) A small dose of human parathyroid hormone(1–34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis. Miner Electrolyte Metab 21:232–235Google Scholar
  25. Sugimoto T, Nakamura T, Nakamura Y et al (2014) Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis. Osteoporos Int 25:1173–1180. doi: View ArticleGoogle Scholar
  26. Toulis KA, Anastasilakis AD, Polyzos SA, Makras A (2011) Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. Hormones 10:174–195View ArticleGoogle Scholar
  27. Weinstein RS, Jilka RL, Almeida M et al (2010) Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Endocrinology 151:2641–2648. doi: View ArticleGoogle Scholar


© The Author(s) 2016